Vet DC
Bringing the Best Human Medicine to Animals

VetDC, Inc.

300 W. Drake Rd.
Fort Collins, CO 80523

Contact: Steven Roy, President and CEO
Email: steven.roy@vet-dc.com
Website: http://www.vet-dc.com
Founded: 2009
Telephone: 303-859-2072
Employees: 5

Description of Company:

VetDC licenses and develops innovative, underutilized human technologies for use in companion animals. By selecting drugs & devices that have already completed preclinical testing, VetDC can leverage substantial prior product investment. This focus dramatically reduces development risk, yielding fast time to market and reduced investment. Our lead product, VDC-1101, is a novel targeted anticancer agent poised for market launch in 2014. It was licensed from Gilead Sciences after extensive testing in 62 client-owned pet dogs with lymphoma. VDC-1101 demonstrated a favorable product profile, with responses exceeding that of conventional lymphoma rescue treatments. Several additional cancer technologies are currently under review.

Market:

Cancer is the leading cause of death in adult pets. Of all pet cancers, lymphoma is one of the most common, afflicting over 200,000 dogs annually in the US. Human chemotherapy drugs are typically used “off-label" in the veterinary setting, with the current US cancer market estimated at $200M. Oncology is one of the fastest growing veterinary specialties, with over 240 board-certified physicians. Recent surveys have shown that 50-80% of pet owners truly consider their pets to be family members and 44% would spend $3,000 or more to treat a life-threatening medical condition - with cancer being one of the biggest concerns for dog & cat owners.
The initial market plan for VDC-1101 is for dogs with B or T cell lymphoma, refractory to conventional therapies, with eventual expansion to first line and feline use, generating nearly $50M in peak annual revenue. The US market for veterinary health expenditure is over $13B and has grown 80% over the last decade.

Management:

- **Steven Roy, President & CEO.** Former Director, Amgen, Inc. with 13 years Licensing/BD and Marketing experience. Led planning and operations for a multi-billion dollar oncology drug launch.
- **Ann Donoghue, Sr. Dir. Regulatory.** DVM and former Development VP with over 20 years product development & regulatory experience at Hoecsht Agri-Vet, Heska and PR Pharmaceuticals, Inc.
- **Doug Johnson, Manufacturing Head.** Former VP of Manufacturing and Process Development at Allos Therapeutics, with 20+ years contract manufacturing experience, specializing in small molecules.
- **Doug Thamm, Head of Clinical.** VMD, Assoc. Prof. Oncology, CSU, with experience conducting over 24 animal cancer trials; recognized veterinary cancer opinion leader.
- **Terry Opgenorth, CSO.** 20+ years biopharma R&D experience; former DVP, Drug Discovery, Abbott.

Recent Milestones:

- VetDC met with the FDA Center for Veterinary Medicine (CVM) in March to review the VDC-1101 safety, efficacy and manufacturing studies. Based on FDA-CVM feedback, VetDC intends to pursue an accelerated or “conditional” approval using the *existing* safety and efficacy technical package, without the need to conduct further trials to meet approval.

Financing:

VetDC received $200K Seed Round funding from CID4 and is presently seeking investors for a $2M Angel Round to complete cGMP manufacturing, formulation, and regulatory work to support VDC-1101 filing with FDA-CVM. Following the Angel Round, VetDC will seek an additional $2-3M to support VDC-1101 commercialization and pipeline development.